Biofrontera, Inc. (BFRI)
| Market Cap | 66.00M |
| Revenue (ttm) | 18.97M |
| Net Income (ttm) | -10.42M |
| Shares Out | 11.00M |
| EPS (ttm) | -0.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About BFRI
Biofrontera is a U.S.-based biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, in particular, diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Our principal product is Ameluz®, which is a prescription drug approved for use in combination with our licensor’s medical device, the BF-RhodoLED® lamp, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate se...
Financial Performance
In 2020, Biofrontera's revenue was $18.85 million, a decrease of -28.01% compared to the previous year's $26.18 million. Losses were -$10.99 million, 0.05% more than in 2019.
Financial StatementsNews
Biofrontera IPO Registration Document (S-1)
Biofrontera, Inc. has filed to go public with an IPO on the NASDAQ.